![]() This article originally appeared on Formulary Watch. “As with all branded products, there will be marketing and awareness activities once RizaFilm is launched, and we expect physicians will prescribe the product. RizaFilm is also protected against generic films for the time being. It is patent protected until July 2034, with our patent listed in the Orange Book,” Godin said.įDA has approved a number of film products the past several years including Belbuca, a film version of buprenorphine that is used to treat chronic pain Sympazan a film version of clobazam, an antiseizure medication and Kynmobi, a film version of apomorphine that is used to Parkinson’s disease. Godin said IntelGenx cannot speculate on whether insurers and payers will cover the treatment, but “we believe the advantages to patients of RizaFilm are clear and are hopeful that it will be covered.” In addition to “providing quick relief for migraine sufferers’ pain,” RizaFilm is “well suited to the approximately 80% of patients who have migraine-related nausea, as well as those who have difficulty swallowing,” Godin said. The global migraine drugs market was valued at nearly $3 billion in 2021 and is expected to reach nearly $11 billion by 2030 - a compound annual growth rate of 15.6%. “Following a successful pre-approval inspection by the FDA of our Montreal manufacturing facility earlier this month, we are thrilled to reach this milestone and excited to soon introduce what will be the first oral thin film for the treatment of acute migraines available in the U.S.” Godin said.Īccording to the American Migraine Foundation, 39 million Americans suffer from migraine. Maxalt MLT, an orally disintegrating tablet, has an extensive packaging system and is cumbersome to carry, Godin said. IntelGenx says RizaFilm was formulated using the VersaFilm, the compnay’s proprietary oral film technology. More people treated with VYEPTI had fewer monthly migraine days with the very first treatment compared with placebo. We’ve been adding new infusion locations Check for one near you. It’s easy to carry and unlike a tablet, does not require water,” Andre Godin, president and CFO of IntelGenx, told Formulary Watch. One 30-minute intravenous (IV) infusion, just 4 times a year. It’s the fastest triptan on the market and is also convenient. “RizaFilm has a number of advantages that make it a compelling treatment option for migraine sufferers. Rizatriptan is the active ingredient in Merck & Co.'s Maxalt. GenscoPharma will commercialize RizaFilm in the U.S. The product was developed by IntelGenx, a Canadian company that specializes in such films. The FDA has approved RizaFilm, a version of the migraine medicine rizatriptan that has been formulated into a thin film that gets absorbed in the mouth.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |